Using a Fragment-Based Approach To Target Protein-Protein Interactions - Test2 - elhamkhani - TriplyDB

Using a Fragment-Based Approach To Target Protein-Protein Interactions

Using a Fragment-Based Approach To Target Protein-Protein Interactions

http://www.wikidata.org/entity/Q27675981

about

Process of Fragment-Based Lead Discovery-A Perspective from NMR Substrate Deconstruction and the Nonadditivity of Enzyme Recognition Engineering archeal surrogate systems for the development of protein-protein interaction inhibitors against human RAD51 BcL-xL conformational changes upon fragment binding revealed by NMR Allosteric modulation of AURKA kinase activity by a small-molecule inhibitor of its protein-protein interaction with TPX2 Contributions of the RAD51 N-terminal domain to BRCA2-RAD51 interaction.Targeting YAP/TAZ-TEAD protein-protein interactions using fragment-based and computational modeling approaches.Overcoming Chemical, Biological, and Computational Challenges in the Development of Inhibitors Targeting Protein-Protein Interactions.Prospective Development of Small Molecule Targets to Oncogenic Ras Proteins A three-stage biophysical screening cascade for fragment-based drug discovery.2P2I HUNTER: a tool for filtering orthosteric protein-protein interaction modulators via a dedicated support vector machine.A structure-guided fragment-based approach for the discovery of allosteric inhibitors targeting the lipophilic binding site of transcription factor EthR.How proteins bind macrocycles.Determination of protein-ligand interactions using differential scanning fluorimetry.Small-molecule inhibitors that target protein-protein interactions in the RAD51 family of recombinases Selective Targeting of the TPX2 Site of Importin-α Using Fragment-Based Ligand Design.Identification of Small-Molecule Inhibitors of the HuR/RNA Interaction Using a Fluorescence Polarization Screening Assay Followed by NMR Validation Small molecules, big targets: drug discovery faces the protein-protein interaction challenge.Quantitative Affinity Determination by Fluorescence Anisotropy Measurements of Individual Nanoliter Droplets.Fragment-based drug discovery as alternative strategy to the drug development for neglected diseases.Flexibility and small pockets at protein-protein interfaces: New insights into druggability.Identification of the β-lactamase inhibitor protein-II (BLIP-II) interface residues essential for binding affinity and specificity for class A β-lactamases A phosphorylation-deubiquitination cascade regulates the BRCA2-RAD51 axis in homologous recombination.Archaeal genome guardians give insights into eukaryotic DNA replication and damage response proteins.Modulating protein-protein interactions: the potential of peptides.K-Ras4B/calmodulin/PI3Kα: A promising new adenocarcinoma-specific drug target?Applications of isothermal titration calorimetry - the research and technical developments from 2011 to 2015.Systematic Targeting of Protein-Protein Interactions High levels of BRC4 induced by a Tet-On 3G system suppress DNA repair and impair cell proliferation in vertebrate cells.3-substituted indazoles as configurationally locked 4EGI-1 mimetics and inhibitors of the eIF4E/eIF4G interaction.Protein crystallography and drug discovery: recollections of knowledge exchange between academia and industry.Studies on the synthesis, stability and conformation of 2-sulfonyl-oxetane fragments.Small molecule probes to target the human Mediator complex.Hot-spot identification on a broad class of proteins and RNA suggest unifying principles of molecular recognition.Peptide-Directed Binding for the Discovery of Modulators of α-Helix-Mediated Protein-Protein Interactions: Proof-of-Concept Studies with the Apoptosis Regulator Mcl-1.Targeting a dynamic protein-protein interaction: fragment screening against the malaria myosin A motor complex.Structure-activity relationship of the peptide binding-motif mediating the BRCA2:RAD51 protein-protein interaction.Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippel-Lindau (VHL) E3 Ubiquitin Ligase: Structure-Activity Relationships Leading to the Chemical Probe (2S,4R)-1-((S)-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-Development of a multipurpose scaffold for the display of peptide loops.Exploring the chemical space of the lysine-binding pocket of the first kringle domain of hepatocyte growth factor/scatter factor (HGF/SF) yields a new class of inhibitors of HGF/SF-MET binding

P2860

Q26738768-F70F286F-B198-4CC0-9350-1FB4A4C6F2DD Q27683622-B109D8E8-FC16-4D33-B39D-5C2A7A8D6BA1 Q27728438-0C32D5E3-8278-4E7F-99B6-52D97C6D5853 Q28533290-E15F8B35-4E13-41BE-90A4-E19054449F1C Q28829011-FFF3984A-5F46-46E3-AC30-7CF7433CDF41 Q30551528-C793D0AF-5D25-4986-9467-FA5C24D80B4A Q33751702-E2939514-E692-43E0-B10C-7C0700DF6DBA Q34481459-9584EF58-348F-45C6-825A-B36F84C21770 Q34481649-CE52260F-E70E-41F7-AD83-BC04C89C74E3 Q35025905-6709F5A6-FF15-4E5F-9ECD-D14C25D868CF Q35033136-B89607D8-A53C-4F13-9E82-ADB8ADA3E5C5 Q35061722-A46948CB-164B-4F94-BC4A-329224EA8005 Q35209183-47211657-77E4-40D8-AAC4-6BF6384575BF Q35303994-D00F1B8C-0171-4F5A-A76F-A3BC46495AE2 Q35484644-9B0C2FAA-664F-4AEB-91F3-3DAC90AAA69A Q35610949-C9A4D4A5-2F3C-44D0-BF74-5AB008BC78E4 Q35781852-4228D049-5892-41B2-A9AD-549226ACC984 Q35981250-4ED271BD-60D0-4304-BA36-E7766F34E4B7 Q36278893-8C255AE5-2C5A-4C9B-B327-0F16E632328E Q36382655-B56D25FB-7B37-4FFA-BC6D-7300B9624D3C Q36501662-B795A9B5-8B16-4C30-A4C7-0183B2D9F9D9 Q36928945-1574CA10-AD45-417D-84EA-F744A4171CEC Q37548532-610B077E-2035-423B-A1BD-32FFAE65E6FA Q37631446-52F7A6F1-7AD4-4AC5-A5D6-1034937BB9D7 Q38314370-473E1ACF-B296-470E-9743-BDFE6F997488 Q38731776-F9BB6463-8BB7-4A86-B8C5-5861AD1CAAE3 Q38843472-39040CD7-20E3-4CDF-AC5C-BE118A41A9A3 Q38856802-3E342EA9-0D1B-42C2-BC5C-FF0FFD17CA1A Q38956850-3220C90F-81E9-492B-B8A2-D3A2149D6B7B Q39031191-A806D42B-E3EB-47DB-8DB3-171550A84C90 Q40065481-1421EB26-71B8-4EEA-86E3-5DE69F71883A Q41097010-D04B6823-35A7-4CCF-BF41-2EB518391D0D Q41370397-EA5AD5F2-6E29-479B-81A7-4A5350294833 Q41512122-A3EC9CFE-0D6F-43D1-87D4-20927A5B31B1 Q41569041-C29365A6-5796-424F-B3DC-0B88B6B7FF37 Q41868298-1B10C6D7-DBB0-4E4C-9C2E-647E9FEA7CC8 Q42837372-F5AEE1CA-CE52-4004-8828-8B2897BA4A52 Q47324161-B2B2F6B0-51AF-4F86-A85B-A962C5C55C7C Q48505189-A7295AE7-CAF5-46DE-95B7-150E0A50D687 Q57360231-10C88782-432E-4DDE-8599-37F3D48CC137

P2860

Using a Fragment-Based Approach To Target Protein-Protein Interactions

http://www.wikidata.org/entity/Q27675981

description

2013 nî lūn-bûn

@nan

2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Using a Fragment-Based Approach To Target Protein-Protein Interactions

@ast

Using a Fragment-Based Approach To Target Protein-Protein Interactions

@en

Using a Fragment-Based Approach To Target Protein-Protein Interactions

@nl

type

label

Using a Fragment-Based Approach To Target Protein-Protein Interactions

@ast

Using a Fragment-Based Approach To Target Protein-Protein Interactions

@en

Using a Fragment-Based Approach To Target Protein-Protein Interactions

@nl

prefLabel

Using a Fragment-Based Approach To Target Protein-Protein Interactions

@ast

Using a Fragment-Based Approach To Target Protein-Protein Interactions

@en

Using a Fragment-Based Approach To Target Protein-Protein Interactions

@nl

P1433

Q27675981-C0ABE386-BE98-4F02-B9A7-A0EEC509E95C

P1476

Q27675981-B18184EE-5C67-4297-9C59-B068A934F37F

P2093

Q27675981-2B229A1E-03F1-45C0-B87B-BC397D2188A9

Q27675981-CE16FB8B-DCA6-49CC-992B-35FBF61B0A1A

Q27675981-F7A0D1A5-9A64-4B27-BCE8-5793A8478154

Q27675981-FD28E875-40AC-4963-85BD-363F6E5A40B2

P2860

Q27675981-08ABAF0F-5419-4CD8-ADBA-A8563BD39449

Q27675981-0AFF0068-129A-49EF-B9EC-4B80D6415241

Q27675981-0B555A32-C6C5-4753-A9C1-56B9D1A3DD88

Q27675981-0F1F2FDC-723C-48D2-9DA1-3A9EEB309160

Q27675981-105A5B9D-9BCA-4D63-8409-DD07BC91942C

Q27675981-15E7EFFA-3B1B-4959-A898-2B24D508801F

Q27675981-167C42E3-3C4E-42B4-9143-3F91F9A41DD7

Q27675981-1808A2D4-8105-4A53-8941-B94D8AF34DFB

Q27675981-1B4147FD-F780-4180-AF2B-757A58B66F08

Q27675981-21E0924F-E6E4-4400-8E37-F3D349E89571

P304

Q27675981-0CB59C7F-8E8C-45DB-908E-B107425E3B7E

P31

Q27675981-038B0FF9-66FC-4485-AFC0-3164C678FC33

P3181

Q27675981-BBC9A6D0-C7FA-4AC4-A33E-0C0F039AD8C9

P356

Q27675981-B3935F91-D52F-4E42-9799-784E7B531F84

P433

Q27675981-28E92031-2352-46E3-95E2-4D978BFE48BC

P478

Q27675981-95D11D74-82DF-4AC3-BABB-FCB08B117191

P50

Q27675981-92DA99C8-391B-42E2-B53F-27E2A404C64E

Q27675981-C0823231-022F-4BDC-8823-2EC1B2724EFC

Q27675981-C4ABEBB2-88F1-4B35-A8DF-D1CBFFF41AA4

Q27675981-C9197DE3-6D22-4FB1-95D7-3F1E29FE8F88

P577

Q27675981-E25B8945-F482-4E47-8054-57A308B45BBE

P5875

Q27675981-7311CB9C-C8B6-4005-89CE-22E8FF3B7257

P698

Q27675981-FC9BC2CA-577E-4C32-84C6-F2C281A60FAA

P932

Q27675981-3AB51C59-FAC7-4774-BA40-928DA76ED3FA

P3181

P356

P1433

P1476

Using a Fragment-Based Approach To Target Protein-Protein Interactions

@en

P2093

Ashok R Venkitaraman

http://www.w3.org/2001/XMLSchema#string

Duncan E Scott

http://www.w3.org/2001/XMLSchema#string

Marko Hyvönen

http://www.w3.org/2001/XMLSchema#string

Matthias T Ehebauer

http://www.w3.org/2001/XMLSchema#string

P2860

Purified human BRCA2 stimulates RAD51-mediated recombination

Insights into DNA recombination from the structure of a RAD51-BRCA2 complex

The BRC repeats of BRCA2 modulate the DNA-binding selectivity of RAD51

PHENIX: a comprehensive Python-based system for macromolecular structure solution

Site-directed ligand discovery

In situ assembly of enzyme inhibitors using extended tethering

Full-length archaeal Rad51 structure and mutants: mechanisms for RAD51 assembly and control by BRCA2

Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL

Discovery and design of novel HSP90 inhibitors using multiple fragment-based design strategies

Recent developments in fragment-based drug discovery

P304

332-42

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

499220

http://www.w3.org/2001/XMLSchema#string

P356

10.1002/CBIC.201200521

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-02-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235367541

http://www.w3.org/2001/XMLSchema#string

P698

23344974

http://www.w3.org/2001/XMLSchema#string

P932

3594973

http://www.w3.org/2001/XMLSchema#string